60 Degrees Pharmaceuticals (SXTP) FCF Margin (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly FCF Margin of 1709.87% for Q1 2026, down 73156.0% year-over-year from N/an in Q1 2025, and down 192.69% quarter-over-quarter from 584.19% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) FCF Margin (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported FCF Margin for 5 consecutive years, with 1709.87% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 73156.0% year-over-year to 1709.87%; the TTM figure through Mar 2026 stood at 812.78% (up 12053.0% YoY), while the FY2025 annual figure was 695.09%, up 25161.0% from the prior year.
- FCF Margin retreated to 1709.87% in Q1 2026 per SXTP's latest filing, from 584.19% in the prior quarter.
- Across five years, FCF Margin topped out at 43.95% in Q4 2023 and bottomed at 7305.38% in Q3 2023.
- Historically, FCF Margin has averaged 1379.15% across 5 years, with a median of 1000.26% in 2024.
- Annual changes were most pronounced in 2023 — FCF Margin sank 712365 bps — and 2024, when it jumped 605255 bps.
- 60 Degrees Pharmaceuticals' FCF Margin stood at 181.73% in 2022, then jumped by 76 bps to 43.95% in 2023, then tumbled by 1443 bps to 677.97% in 2024, then gained by 14 bps to 584.19% in 2025, then tumbled by 193 bps to 1709.87% in 2026.
- Business Quant data shows SXTP's FCF Margin at 1709.87% in Q1 2026, 584.19% in Q4 2025, and 484.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -1,073.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,709.87% |
| Dec 31, 2025 | -584.19% |
| Sep 30, 2025 | -484.25% |
| Jun 30, 2025 | -1,483.62% |
| Mar 31, 2025 | -978.31% |
| Dec 31, 2024 | -677.97% |
| Sep 30, 2024 | -1,252.83% |
| Jun 30, 2024 | -1,022.22% |
| Mar 31, 2024 | -1,079.89% |
| Dec 31, 2023 | -43.95% |
| Sep 30, 2023 | -7,305.38% |
| Jun 30, 2023 | -81.46% |
| Mar 31, 2023 | -2,422.37% |
| Sep 30, 2022 | -181.73% |